Does phospholipase A2 group IIA expression correlate with prolonged survival in gastric cancer?
  PLA2G2A may predict survival and might be a potential biomarker for early detection and individualized therapy.
The results suggest that treatment of patients with GLN-supplemented PN may decrease infectious morbidity rate compared with those who treated with nonenriched PN.